Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
SMARCA4 and EZH2 are two functional key players of their respective antagonizing chromatin remodeling complexes SWI/SNF and PRC2. EZH2 inhibitory drugs may abrogate pro-oncogenic features of PRC2 and turn the balance to cell differentiation via SWI/SNF activity in cancers.
SMARCA4
and
EZH2
expression was assessed by RT-PCR in 238 epithe...
Alternative Titles
Full title
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c0f898d9b817455c806a36660ea6347a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c0f898d9b817455c806a36660ea6347a
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-020-77532-x
